Glen UnySupportTM HybridCPGTM

default
28-5040
N-Methyl-succinimido[3,4-b]-7-oxabicyclo[2.2.1]heptane-6-(4,4'-dimethoxytrityloxy)-5-succinoyl long chain alkylamino HybridCPGTM

Product Specifications

Catalog Number: Select Pack Size and Format to Reveal

Description

HybridCPG™ consists of CPG particles conformally coated with a very thin crosslinked polymer film based on polystyrene. The molecular structure of the polymer coating is designed to have a very high density of evenly distributed attachment points for optimum oligo synthesis. In this way, the pore size to loading density trade-off is minimized and the chemical resistance to glass-aggressive reagents is greatly improved. Although the nano-scale coating is subject to swelling, the rigid pore structure of the CPG substrate accommodates this and, at the same time, maintains a uniform pore space for the oligo synthesis. Thus, HybridCPG exhibits no bulk swelling in the synthesis solvents and allows much higher ligand loadings for a given pore size compared to conventional CPG. Glen Research is partnering with Prime Synthesis, developers of HybridCPG, to introduce our two popular Universal Supports, Glen UnySupport™ and Universal Support III, on HybridCPG.

Details

Usage

  • Coupling: This support should be used in a manner identical to normal protected nucleoside support since it contains the DMT group.
  • Deprotection: Solution phase: Ammonium Hydroxide:MethylAmine (AMA) 1:1 for 1 hour at 65°C or Ammonium Hydroxide for 8 hours at 55°C. For sensitive minor bases or dyes, Glen UnySupport may be eliminated with 50 mM Potassium Carbonate in Methanol in 17 hours at room temperature or with Tert-Butylamine/water 1:3 (v/v) for 4 hours at 60°C. Gas Phase: Methylamine gas for 30 minutes at 65°C at 30 psi.
Specifications
Storage Controlled room temperature or lower, dry

Intellectual Property

This product is covered by US Patent 7,202,264 owned by Ionis Pharmaceuticals, Inc..